Completed

Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL Model TFNT00

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL

Device
Who is being recruted

Cataract

+ Eye Diseases

+ Lens Diseases

Over 22 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: September 2015
See protocol details

Summary

Principal SponsorAlcon Research
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 7, 2015

Actual date on which the first participant was enrolled.

This study will be conducted in regions where the test article is approved at the time of study start.

Official TitleInvestigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL Model TFNT00
NCT02529488
Principal SponsorAlcon Research
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

167 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 22 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

CataractEye DiseasesLens Diseases

Criteria

4 inclusion criteria required to participate
Diagnosis of bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision;
Able to comprehend and willing to sign informed consent and complete all required postoperative follow-up procedures;
Clear intraocular media other than cataract in both eyes;
Other protocol-specified inclusion criteria may apply.
6 exclusion criteria prevent from participating
Clinically significant corneal abnormalities including corneal dystrophy, inflammation or edema;
Ocular trauma, corneal transplant, retinal conditions, degenerative eye disorders, or color vision deficiencies;
Glaucoma (uncontrolled or controlled with medication) or ocular hypertension;
Pregnant or lactating;
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers